Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 01, 2024

Asciminib Monotherapy for T315I-Mutated Chronic-Phase Chronic Myeloid Leukemia After ≥1 Prior TKI

Leukemia

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Leukemia 2024 May 16;[EPub Ahead of Print], JE Cortes, K Sasaki, DW Kim, TP Hughes, G Etienne, MJ Mauro, A Hochhaus, F Lang, MC Heinrich, M Breccia, M Deininger, YT Goh, JJWM Janssen, M Talpaz, VGG de Soria, P le Coutre, DJ DeAngelo, A Damon, S Cacciatore, F Polydoros, N Agrawal, D Rea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading